Skip to main content
Top
Published in: Dermatology and Therapy 1/2014

Open Access 01-06-2014 | Original Research

Psoriasis Causes Significant Economic Burden to Patients

Authors: A. Mustonen, K. Mattila, M. Leino, L. Koulu, R. Tuominen

Published in: Dermatology and Therapy | Issue 1/2014

Login to get access

Abstract

Introduction

Psoriasis results in expenses to patients from many cost sources. Psoriasis treatments may result in considerable time and traveling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the multidimensional economic burden of psoriasis to patients.

Methods

The study was based on 232 Finnish patients with psoriasis or psoriatic arthritis visiting a tertiary level dermatological clinic during a 1-year study period between October 1, 2009 and September 30, 2010. The data were based on a patient questionnaire, clinical data from the medical records and reimbursement data from the Finnish Social Insurance Institution. Item costs were based on true costs charged from the patients and all time cost estimates were based on the Human Capital Approach method.

Results

199 patients with psoriasis and 33 with psoriatic arthritis were included in the study. Total costs were higher for patients receiving traditional systemic medications or phototherapy than those not receiving such treatment. Travel costs and travel time costs accounted for more than 60% of the costs of phototherapy. Skin care at home was time consuming and thus caused significant burden to patients. The majority of the visit costs arose from hospital visits and only a small proportion were attributed to visiting primary health care providers.

Conclusion

Visit charges and other patient co-payments were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and lost time comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.
Appendix
Available only for authorised users
Literature
1.
go back to reference Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008;26(5):424–31.PubMedCrossRef Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008;26(5):424–31.PubMedCrossRef
2.
go back to reference Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16–7.PubMedCrossRef Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16–7.PubMedCrossRef
3.
go back to reference Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.PubMedCrossRef Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.PubMedCrossRef
4.
go back to reference Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol. 1996;35(12):1289–91.PubMedCrossRef Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol. 1996;35(12):1289–91.PubMedCrossRef
5.
go back to reference Lambert J, Dowlatshahi EA, de la Brassinne M, Nijsten T. A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO). Eur J Dermatol. 2012;22(2):231–7.PubMed Lambert J, Dowlatshahi EA, de la Brassinne M, Nijsten T. A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO). Eur J Dermatol. 2012;22(2):231–7.PubMed
6.
go back to reference Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol. 2007;143(9):1113–21.PubMedCrossRef Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol. 2007;143(9):1113–21.PubMedCrossRef
7.
go back to reference Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30(11):1005–13.PubMedCrossRef Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30(11):1005–13.PubMedCrossRef
8.
go back to reference Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212(2):137–44.PubMedCrossRef Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212(2):137–44.PubMedCrossRef
9.
go back to reference Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly. 2010;140(5–6):85–91.PubMed Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly. 2010;140(5–6):85–91.PubMed
10.
go back to reference Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3(7):511–8.PubMedCrossRef Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3(7):511–8.PubMedCrossRef
11.
go back to reference Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075–82.PubMed Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075–82.PubMed
12.
go back to reference Schoffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5(3):209–18.PubMedCrossRef Schoffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007;5(3):209–18.PubMedCrossRef
13.
go back to reference Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden—a cross-sectional study. Eur J Dermatol. 2012;22(2):238–45.PubMed Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden—a cross-sectional study. Eur J Dermatol. 2012;22(2):238–45.PubMed
14.
go back to reference Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23(2):208–11.PubMed Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23(2):208–11.PubMed
15.
go back to reference Ruano J, Isla-Tejera B, Jimenez-Puya R, Rodriguez-Martin A, Cardenas M, Gomez F, et al. Long-term cost-effectiveness analysis of etanercept and adalimumab for plaque psoriasis not associated with arthritis. Dermatol Ther (Heidelb). 2013;3(2):131–42.CrossRef Ruano J, Isla-Tejera B, Jimenez-Puya R, Rodriguez-Martin A, Cardenas M, Gomez F, et al. Long-term cost-effectiveness analysis of etanercept and adalimumab for plaque psoriasis not associated with arthritis. Dermatol Ther (Heidelb). 2013;3(2):131–42.CrossRef
16.
go back to reference Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7(2):157–67.PubMedCrossRef Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7(2):157–67.PubMedCrossRef
17.
go back to reference Yentzer BA, Feldman SR. Trends in home phototherapy adoption in the US: monetary disincentives are only the tip of the iceberg. J Dermatol Treat. 2011;22(1):27–30.CrossRef Yentzer BA, Feldman SR. Trends in home phototherapy adoption in the US: monetary disincentives are only the tip of the iceberg. J Dermatol Treat. 2011;22(1):27–30.CrossRef
18.
go back to reference Hankin CS, Feldman SR, Szczotka A, et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200–14. Hankin CS, Feldman SR, Szczotka A, et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200–14.
19.
go back to reference Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat. 2006;17(1):29–37.CrossRef Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat. 2006;17(1):29–37.CrossRef
20.
go back to reference Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4(9):1525–33.PubMedCrossRef Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4(9):1525–33.PubMedCrossRef
21.
go back to reference Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatol Treat. 2011;22(2):65–74.CrossRef Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatol Treat. 2011;22(2):65–74.CrossRef
22.
go back to reference de Rie MA, de Hoop D, Jonsson L, Bakkers EJ, Sorensen M. Pharmacoeconomic evaluation of calcipotriol (Daivonex/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for The Netherlands. Dermatology. 2001;202(1):38–43.PubMedCrossRef de Rie MA, de Hoop D, Jonsson L, Bakkers EJ, Sorensen M. Pharmacoeconomic evaluation of calcipotriol (Daivonex/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for The Netherlands. Dermatology. 2001;202(1):38–43.PubMedCrossRef
23.
go back to reference Uttjek M, Dufaker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol. 2004;84(1):37–43.PubMedCrossRef Uttjek M, Dufaker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol. 2004;84(1):37–43.PubMedCrossRef
24.
go back to reference Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33.PubMedCrossRef Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33.PubMedCrossRef
25.
go back to reference Carrascosa JM, Pujol R, Dauden E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006;20(7):840–5.PubMed Carrascosa JM, Pujol R, Dauden E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol. 2006;20(7):840–5.PubMed
26.
go back to reference Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatol Treat. 2005;16(1):37–42.CrossRef Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatol Treat. 2005;16(1):37–42.CrossRef
27.
go back to reference Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R. The costs of psoriasis medications. Dermatol Ther (Heidelb). 2013;3(2):169–77.CrossRef Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R. The costs of psoriasis medications. Dermatol Ther (Heidelb). 2013;3(2):169–77.CrossRef
28.
go back to reference Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6.PubMedCrossRef Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6.PubMedCrossRef
29.
go back to reference Wong JW, Davis SA, Feldman SR, Koo JY. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012;11(8):957–62.PubMed Wong JW, Davis SA, Feldman SR, Koo JY. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012;11(8):957–62.PubMed
30.
go back to reference Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343–53.PubMedCrossRef Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy. 2012;10(5):343–53.PubMedCrossRef
Metadata
Title
Psoriasis Causes Significant Economic Burden to Patients
Authors
A. Mustonen
K. Mattila
M. Leino
L. Koulu
R. Tuominen
Publication date
01-06-2014
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2014
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-014-0053-2

Other articles of this Issue 1/2014

Dermatology and Therapy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.